AMENDMENT No. 1 to the Collaboration Agreement between Novartis Pharma AG and Amgen Inc.Amgen Inc • April 25th, 2018 • Biological products, (no disgnostic substances)
This Amendment No. 1 (“Amendment”) is entered into as of March 20, 2018 (“Amendment No. 1 Effective Date”) by and between Novartis Pharma AG, a Swiss corporation having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”), and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA (“Amgen”). Novartis and Amgen are each referred to individually as a “Party” and together as the “Parties”.
AMENDMENT NO. 1 TO THE CREDIT AGREEMENTThe Credit Agreement • April 25th, 2018 • Amgen Inc • Biological products, (no disgnostic substances) • New York
AMENDMENT NO. 1 TO THE CREDIT AGREEMENT among Amgen Inc., a Delaware corporation (the “Company”), the banks, financial institutions and other institutional lenders parties to the Credit Agreement referred to below (collectively, the “Banks”) and Citibank, N.A., as administrative agent (the “Administrative Agent”) for the Banks.
